Galapagos NV: business update: http://t.co/6w1jppWE
posted 4 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Trinean NV today announced the appointment of Philippe Stas as it’s new CEO, succeeding Dr. Marc Zabeau, who remains a member of the board of directors. Simultaneously, Trinean announced that the company has secured 2.7 million euro of growth financing provided by its existing investors. read more
Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has submitted a Clinical Trials Application (CTA) to the European regulatory authorities to start a Phase I clinical trial with a Nanobody® for the treatment of Alzheimer's disease. The Nanobody has been developed as part of the collaboration signed between Ablynx and Boehringer and the event triggers a €1 million milestone payment to Ablynx. read more
QUINVITA, the Industrial Crop Technology Company today announced the closure of its capital round, raising EUR 1.5 million from a group of investors including Think2Act Arkiv, Group Vanden Avenne Izegem and a number of private investors. read more
Ablynx [Euronext Brussels: ABLX] today announced that it has received a €400,000 milestone payment from its collaboration with Novartis. The payment was triggered by the approval of an Investigational New Drug (IND) application from the U.S. Food and Drug Administration for the Phase I clinical trial for a Nanobody® licensed to Novartis. This is the first development candidate emerging from the licensing agreement between Ablynx and Novartis. read more
ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has raised €77.8 million through a private placement via an accelerated bookbuilding procedure announced on Wednesday 28 March 2012 after the market closed. read more
